Komori
CellSource (4880) · InitiativeAdvanced

Expansion of Medical Equipment Sales

First written in FY2024-Q1. 4 of 8 entries say "Softened", first in FY2025-H1. Latest entry: 2026-09-08.

8entries
3years
3from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseAdvancedFY2024-Q2SoftenedFY2025-H1 – 2026-03-172024: 220242025: 120252026: 52026
Same theme, other companies
Revenue Growth and Profit Fluctuations in the Medical Device Sales BusinessA theme 2 companies write about · 0 as a headwind · 2 as a tailwind

0 other companies' latest entry also says "Advanced".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. 2026-09-08AdvancedResults briefing materials

    「Medical device sales +¥57 million (+8%)」

    Medical device sales increased by ¥57 million, or 8%, year on year.
  2. FY2026-H1AdvancedAnnual report

    「In medical device sales, we primarily sell medical devices, including liposuction equipment, to medical institutions such as cosmetic clinics. Sales for the interim consolidated period increased 0.8% year on year to ¥426.378 million, reflecting increased sales to business partners.」

    Medical device sales increased 0.8% year on year to ¥426.378 million, driven by higher sales to business partners.
  3. FY2025SoftenedAnnual report

    「In medical device sales, we primarily sell medical devices, including liposuction equipment, to medical institutions such as cosmetic clinics. Sales for the consolidated fiscal year amounted to ¥756.940 million, reflecting a decline in sales to business partners.」

    Medical device sales continued to decline from the previous interim period, resulting in full-year sales of ¥756.940 million.
  4. FY2025-H1SoftenedAnnual report

    「In medical device sales, we primarily sell medical devices, including liposuction equipment, to medical institutions such as cosmetic clinics. Sales for the cumulative interim consolidated period amounted to ¥422.930 million, reflecting a decline in sales to business partners.」

    Medical device sales declined to business partners, and sales for the interim consolidated period amounted to ¥422.930 million.
  5. FY2024-Q2AdvancedAnnual report

    「In medical device sales, we primarily sell medical devices, including liposuction equipment, to medical institutions such as cosmetic clinics. Sales for the cumulative second quarter increased 35.6% year on year to ¥486.358 million, reflecting expanded sales to business partners.」

    Expanded sales to business partners drove cumulative second-quarter medical device sales to ¥486.358 million, up 35.6% year on year.
  6. FY2024-Q1First statedAnnual report

    「In medical device sales, we primarily sell medical devices, including liposuction equipment, to medical institutions such as cosmetic clinics. Sales for the cumulative first quarter increased 64.7% year on year to ¥297.761 million, reflecting expanded sales to business partners.」

    Expanded sales to business partners drove first-quarter medical device sales up 64.7% year on year to ¥297.761 million.
Moved together

"Expansion of the Direct-Sales Model and Growth in the OEM Product Lineup" moved the same way as this thread, in the same document, in 5 of its 8 moves.

533222★123456
  1. ★This thread
  2. 1Expansion of the Direct-Sales Model and Growth in the OEM Product Lineup5×
  3. 2Expanding and stabilizing the current business and laying the groundwork for the next phase of growth3×
  4. 3Increase in Partner Medical Institutions and Expansion into New Treatment Areas3×
  5. 4Revenue and Profit Growth Since Founding and Expansion of the Regenerative Medicine-Related Business2×
  6. 5Implementation of regenerative medicine in society and management support for medical institutions2×
  7. 6Dilution of Equity Value from Stock Acquisition Rights2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for CellSource yet. It last moved in the Results briefing materials of 2026-09-08: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Expansion of Medical Equipment Sales | CellSource Co.,Ltd. (4880) | Komori